HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
BIOBOARD - AUSTRALIA
Women: Hormone therapy won’t harm your head
Women do not suffer cognitive loss when taking hormone replacement therapy to treat symptoms of menopause, a new study finds.

Researchers tested the treatment for six months in early postmenopausal women between the ages of 49 and 55 who had never used HRT E2D—a combination of hormones estradiol and drospirenone. The examined HRT's effects on memory, language and concentration.

The treatment resulted in significant improvement in menopausal symptoms including hot flushes, night sweats, and sexual function, and it lowered blood pressure and weight in comparison to those who were treated with an identical placebo.

The women underwent cognitive assessment and were asked to perform mental tasks during a brain-imaging (MRI) scan. The researchers found no effect on the cognitive performance of early postmenopausal women.

Professor Susan Davis, director of the Women's Health Research Program in the Monash University School of Public Health and Preventive Medicine, says there had long been debate about the safety of hormone replacement therapies and the potential adverse effects on cognitive function in women.

Davis says memory and mood complaints were frequent in women after menopause due to oestrogen deficiency, including a lack of clarity of thought and memory or word-finding difficulties.

“These findings are reassuring for women,” Davis says.

“We report, for the first time, that drospirenone combined with estradiol has no overall effect on the cognitive performance of postmenopausal women examined over a 26-week period.

“Although hormone replacement therapy is no quick fix to the challenge of menopause, it does show that the E2D treatment can be useful in the overall management of menopause, and without adversely effecting cognitive ability.”

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy